Burcon NutraScience increases placement to $6.9-million

Executive Summary

• Burcon NutraScience Corp. has increased the size of its non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million, citing strong investor demand.
• Insiders and the company's manufacturing partner owners have committed to participating in the financing with a minimum investment of $5.0 million in principal amount.
• The financing is conditionally approved by the Toronto Stock Exchange (TSX) and remains subject to disinterested shareholder approval.

Key Details

• Financing Structure: Non-brokered private placement of convertible debentures.
• Total Size: Increased to an aggregate principal amount of up to $6.9 million.
• Insider Commitment: Insiders and Burcon's manufacturing partner owners are committed to a minimum participation of $5.0 million in principal amount.
• Regulatory Status: Conditionally approved by the Toronto Stock Exchange (TSX).
• Conditions: Subject to Burcon complying with TSX terms, specifically the receipt of disinterested shareholder approval.
• Strategic Context: CEO Kip Underwood stated the capital will help accelerate the production and sales timeline and reaffirm the revenue target of more than $10 million for calendar 2026.

Notable Quotes

• "We are encouraged by the strong investor interest in a challenging market," said Kip Underwood, Burcon's chief executive officer. "With continued support from insiders and major shareholders, we are accelerating our production and sales timeline and reaffirm our revenue target of more than $10-million for calendar 2026."